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Introduction: Outcomes related to Covid-19 in systemic sclerosis (SSc) patients could be 
influenced by internal organ involvement and/or immunosuppressive treatment, leading to 
efforts to shield patients from Covid-19 transmission. We examined the impact of Covid-19 
on the lived experience of SSc with regards to other aspects of daily living including 
occupation and emotional well-being. 
 
Method: Individuals with SSc or relatives/carers participated in an online survey, 
disseminated through international patient associations and social media pages, designed to 
examine the impact of Covid-19 on living with a rare disease. 
 
Results: Responses from 121 individuals (98% were patients with SSc) from 14 countries 
were evaluable. Covid-19 was considered a probable/definite personal threat (93%) or 
threat for the individual they care for (100%). Approximately two-thirds of responders 
reported either cancellation or postponement/delay to appointments, diagnostic tests, 
medical therapies at home (e.g. infusions), surgery or transplant, psychiatry follow-up, or 
rehabilitation services. Twenty-six per cent reported at least one SSc medicine/treatment 
had been unavailable, and 6% had to either stop taking usual medications or use an 
alternative. Most reported online consultations/telemedicine via phone (88%) and online 
(96%) as being ‘fairly’ or ‘very’ useful. Respondents reported tensions amongst family 
members (45%) and difficulty overcoming problems (48%). Restrictions on movement left 
around two-thirds feeling isolated (61%), unhappy and/or depressed (64%), although the 
majority (85%) reported a strengthening of the family unit. 
 
Conclusions: Covid-19 has resulted in significant impact on the clinical-care and emotional 
well-being of SSc patients. Changes to clinical care delivery have been well-received by 
patients including telemedicine consultations.  
 
 





Systemic sclerosis (SSc) carries a significant burden of disease-associated morbidity including 
reduced quality of life and high-associated mortality (1–4). Therefore, patients require 
regular clinical follow-up including screening for cardiorespiratory complications which can 
significantly improve survival (e.g. through the early detection of pulmonary hypertension) 
[5,6]. SSc is associated with significant emotional and social consequences including (but not 
limited to) anxiety, depression, fatigue, sleep disorders, body image dissatisfaction and 
sexual dysfunction. Patients experience fear and uncertainty about the future and make 
many adaptations to self-manage their condition. For example, patients describe the need 
for constant vigilance and cold avoidance to prevent attacks of Raynaud’s phenomenon 
and/or the development of new digital ulcers [7,8]. Patients with SSc also potentially require 
hospitalisation (both electively and urgently) throughout the course of their disease, 
including for the administration of intravenous-based vascular and immunosuppressive 
therapies. Furthermore, there still remains significant debate about the optimal timing for 
the safe reintroduction of immunosuppressive therapies in the context of confirmed Covid-
19 infection [9]. 
 
Patients with SSc are potentially extremely vulnerable to poor outcomes including high 
mortality from Covid-19 (SARS-Cov-2) as a consequence of underlying major internal organ 
involvement and/or immunosuppressive treatment. A particular concern is the high 
prevalence of interstitial lung disease in SSc and potential lung injury related to Covid-19 
infection [10,11]. There are also significant diagnostic challenges because Covid-19 
pneumonia can share many similar radiological abnormalities with SSc-interstitial lung 
disease (e.g. ground glass opacities) [10,11]. In addition to the direct threats relating to 
Covid-19, patients with SSc have also faced disruption to their previous standards of care 
relating to ‘in person’ clinic appointments, therapeutic drug infusions, commencement of 
new immunomodulatory therapy and hospital-based investigations such as 
cardiopulmonary screening and cross-sectional imaging. However, international 
adjustments to the delivery of clinical care and new ways of working are likely to improve 
future care in SSc [12]. 
 
 
Against this background, our aims were to examine the impact of the Covid-19 pandemic on 
patients’ with SSc 1) clinical-care and 2) other aspects of daily life including occupation and 





An international survey was designed by EURORDIS-Rare Diseases Europe, a non-profit and 
non-governmental alliance of over 900 patient organisations to understand how patients 
with rare disease experience the Covid-19 pandemic. The link to the survey was widely 
distributed including via the EURORDIS website [13], patient organisations and on social 
media pages. The survey was translated into 23 languages in order to ensure broad 
geographical patient representation. The survey took place between April and May 2020; 
either the patient themself or a patient representative (relative/carer) could complete the 
survey. The survey (see supplementary data) was comprised of 30 questions which included 
patients’ demographic information, current measures in place against the Covid-19 
pandemic and the perceived threat, interruption and the perceived impacts in usual aspects 
of their clinical-care, changes to their occupation, and their emotional well-being. All 
responses were fully anonymised and there was no opportunity to verify diagnoses or 
responses. Respondents provided implied consent through completion of the voluntary 
survey. In view of the nature and distribution of the survey, the work was exempt from UK 




A total of 121 individuals, the majority of which were patients with SSc, responded to the 
survey from 14 countries worldwide. Most (>80%) individuals (‘responders’) reported living 
in Europe, with the majority in Italy (26%), Denmark (25%), Spain (18%), France (9%) or 
England (6%). When reported (n=118), the survey was completed by patients themselves 
(98%) or by their spouse or a patient representative (2%). The majority of responders were 
female (93%). Most (95%) responders were older than 35 years; in particular, either 
between 35-49 years (37%) or 50-64 years (45%). Less than one fifth of responders were 
either 65 years or older (13%) or between 25-34 years (5%). Almost all (99%) responders 
identified that social distancing was in place including avoiding mass gatherings and 
maintaining distances from others when possible.  
 
Perceived impact and threat of Covid-19 
Over half of respondents indicated that the interruptions related to the Covid-19 pandemic 
were either ‘probably’ or ‘definitively’ affecting patients’ health (59%) or well-being (69%). 
The majority of respondents (n=121) felt that Covid-19 posed either a ‘high’ (54%) or ‘very 
‘high’ (39%) personal threat. Around three-quarters felt that they had access to all the 
information they needed either ‘some’ (28%) or ‘most’ (44%) of the time.  
 
Impact of Covid-19 on clinical-care 
Two-thirds of patients (63%) were receiving at least part of their clinical care for SSc through 
a hospital. Of these, half (52%) did not attend the hospital themselves because they were 
fearful of contracting Covid-19. Respondents also indicated that they had been told not to 
attend the hospital if they became unwell for reasons other than Covid-19 (41%) or that the 
hospital/unit which provides care for SSc was closed (21%).  
 
Figure 1 depicts the reported interruption in different aspects of care for patients with SSc 
provided by healthcare professionals since the beginning of the Covid-19 pandemic. Around 
two-thirds of responders reported either complete cancellation or postponement/delay to 
appointments with clinicians who manage their SSc, diagnostic tests (including blood tests, 
medical imaging and cardiorespiratory investigations), medical therapies at home (e.g. 
infusions), surgery or transplant, psychiatry follow-up, or rehabilitation services. One 
quarter (26%) of responders identified that at least one of their medicines/treatments 
needed for SSc had been unavailable temporarily when they visited their pharmacy or 
hospital, and 6% had to either stop taking it or take an alternative. Of those currently 
unaffected by disruptions to their medicines or treatment (n=82), the majority were either 
afraid ‘a little’ (55%) or ‘a lot’ (13%) about future possible problems if the pandemic 
continues.  
 
Experience of changes to clinical-care 
The majority of responders (where applicable) indicated that their experience to changes in 
clinical-care was either ‘fairly’ or ‘very’ useful with prescription by email (94%), online 
consultations or other forms of telemedicine including via telephone (88%), and online 
education and training to help them manage their SSc (96%). 
 
Impact of Covid-19 on occupation and emotional well-being 
Impact on occupation 
The majority (90%) of respondents (where applicable, n=41) indicated that they had made 
changes to their working situation since the Covid-19 pandemic. Almost two-thirds were 
working from home (59%), 17% had to stop working and 15% significantly reduced their 
number of working hours.  
 
Impact on emotional well-being 
Figure 2 depicts the reported impact on patients with SSc emotional well-being since the 
Covid-19 pandemic. Respondents indicated that they felt tensions between their family 
members (45%), ‘sometimes’, ‘often’ or ‘very often’, they felt that they could not overcome 
their problems (48%), and two-thirds felt isolated (61%) or unhappy and/or depressed 
(64%). However, over three-quarters (85%) felt a strengthening of the family unit resulting 
from the Covid-19 pandemic.  
 
Conclusions 
The key findings from our study are that the Covid-19 pandemic has significantly impacted 
usual clinical-care, occupation and emotional well-being of patients with SSc. Patients 
experienced interruptions in all aspects of their clinical care including consultations, access 
to investigations including cardiorespiratory imaging, and access to drug therapies. Patients 
and their caregivers feel that these interruptions are likely to have a significant detrimental 
impact on the health of patients with SSc. The Covid-19 pandemic is having a major impact 
on the working life and emotional well-being of patients with SSc. However, in response 
there is evidence that the family unit is strengthening in order to face this unique challenge. 
Adding to an already unpredictable disease, the Covid-19 pandemic has been associated 
with significant fear and uncertainty about the future for patients with SSc and their 
caregivers. Clinicians are faced with the challenge of maintaining a crucial continuity of care 
for patients with SSc, including psychological support and medicines management. 
 
Patients with SSc require close clinical review and timely access to potentially tissue saving 
therapies. As the Covid-19 pandemic continues, clinicians are rapidly adopting existing and 
new technologies to provide clinical care including consultations and renewal of prescribed 
therapies. The vast majority (~90%) of responders felt that such alternative methods were 
either ‘fairly’ or ‘very’ useful. Ciurea and colleagues [14] recently reported their experience 
from the Swiss Clinical Quality Management cohort of the impact of the Covid-19 pandemic 
on the disease activity of patients with inflammatory rheumatological conditions (axial 
spondlyloarthritis, rheumatoid arthritis and psoriatic arthritis). Despite a reduction in the 
number of consultations by half (52%) the number of remote assessments more than 
doubled. Reassuringly, the proportion of patients with disease flares remained stable and 
there was no detrimental impact on disease activity as assessed by patient-reported 
outcome measures. Accurate identification of patients with SSc and major internal organ-
based complications (e.g. pulmonary hypertension and/or interstitial lung disease) [15] is 
required, with appropriate advice to shield  
 
Patients with SSc and their caregivers require high-quality accessible information of 
appropriate readability throughout the course of their disease and are increasingly using 
internet/online sources of information and support (including patient-led organisations) to 
inform shared decision making [16,17]. However, of concern, the overall quality and 
readability of internet-based SSc (and Raynaud’s phenomenon) information (prior to the 
Covid-19 pandemic) has been reported to be poor [18]. In response to the Covid-19 
pandemic, the World Scleroderma Foundation (WSF) has developed preliminary practical 
advice based for patient management which were developed virtually by experts in 
rheumatology and associated specialities [10]. This includes the need to limit visits to the 
hospital/clinic and that this must be balanced against the risk of disease flare on the 
individual level [10]. Also, telemedicine consultations have been strongly endorsed [10]. 
Furthermore, it has been acknowledged that temporary drug interruption of 
immunosuppressive treatment may be considered in Covid-19 infection, again highlighting 
the need to balance the risk of disease flare, and also the need for future research in this 
area [10]. At the present time, no change in vascular/vasoactive therapy has been proposed 
for vascular and renal involvement in patients with SSc at risk of developing or experiencing 
Covid-19 [10].  
 
As expected, in the earlier stages of the rapidly developing Covid-19 pandemic there were 
significant interruptions to existing treatment for patients with SSc. For example, Crisafulli et 
al [19], reported their single-centre (Brescia, Italy) early experience (since 23rd January) of an 
adapted, centralised outpatients for patients with rheumatic diseases. Of 64 patients with 
SSc who were receiving periodic intravenous iloprost infusions, the majority (73%) briefly 
discontinued their iloprost therapy. Despite interruption in treatment, there was no 
significant increase in new digital ulcers, but a slight increase in ulcer severity. A key aspect 
is that throughout this period there was regular communication with patients with SSc to 
optimise the timely reintroduction of treatment. There are also potential opportunities to 
learn from innovative models of care that have been developed in response to the Covid-19 
pandemic in other chronic health conditions (e.g., diabetes mellitus) (20). 
 
The EURORDIS survey has a number of important points for consideration. Although the 
sample size was fairly small (n=121) it has benefited from widespread geographical 
participation from patients with SSc, including translation of the survey into 23 languages. 
The survey was conducted towards the beginning of the Covid-19 pandemic and therefore 
responders’ attitudes and beliefs, and their experience of managing SSc, may have changed 
during the evolving crisis, including through adaptations and changing governmental 
guidance. Also, specific disease-related information (e.g., disease subtype and severity) was 
not collected as these factors may have important implications for the impact of the Covid-
19 pandemic in patients with SSc. Further research is required to examine the impact on the 
lived experience of patients with SSc between the first and subsequent ‘waves’ of the 
pandemic including once vaccination is available.’ 
 
In conclusion, the Covid-19 pandemic has resulted in significant impact on patients with SSc 
routine clinical-care and emotional well-being. Changes to the delivery of different aspects 
of clinical care have been well-received by patients with SSc, including telemedicine 
consultations and further research is now required to understand the utility potential, 
effectiveness and sustainability of these interventions. The potential for future pandemics 
also underlines the importance of rising to the challenge of maintaining a continuity of care 
for patients who require regular clinical follow-up.  Patients with SSc require careful 
individual assessment to determine their risk of disease flare from interruptions in 
treatment. There are still many practical uncertainties about patient management in Covid-
19 and future research is urgently needed to understand the interventions that can ensure 
continuity of care for a global challenge that may ‘never go away’. 
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Figure 1: Reported interruption in aspects of usual clinical care provided by healthcare 






Figure 2: Impact on patients with SSc emotional well-being since the beginning of the Covid-
19 pandemic.  
 
 
 
 
